From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research"

Cabrera-Fuentes HA 1 , Aragones J 2 , Bernhagen J 3 , Boening A 4 , Boisvert WA 5 , Bøtker HE 6 Show all authors , Bulluck H 7 , Cook S 7 , Di Lisa F 8 , Engel FB 9 , Engelmann B 10 , Ferrazzi F 11 , Ferdinandy P 12 , Fong A 13 , Fleming I 14 , Gnaiger E 15 , Hernández-Reséndiz S 7 , Kalkhoran SB 16 , Kim MH 17 , Lecour S 18 , Liehn EA 19 , Marber MS 20 , Mayr M 21 , Miura T 22 , Ong SB 7 , Peter K 23 , Sedding D 24 , Singh MK 7 , Suleiman MS 25 , Schnittler HJ 26 , Schulz R 27 , Shim W 28 , Tello D 2 , Vogel CW 29 , Walker M 16 , Li QO 2 , Yellon DM 16 , Hausenloy DJ 30 , Preissner KT 1

Affiliations 

  • 1 Institute of Biochemistry, Medical School, Justus-Liebig University, Giessen, Germany
  • 2 Research Unit, Hospital of Santa Cristina, Research Institute Princesa, Autonomous University of Madrid, Madrid, Spain
  • 3 Department of Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany
  • 4 Department of Cardiovascular Surgery, Medical School, Justus-Liebig-University, Giessen, Germany
  • 5 Department of Microbiology, Kazan Federal University, Kazan, Russian Federation
  • 6 Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N, Denmark
  • 7 Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, 8 College Road, Singapore, 169857, Singapore
  • 8 Department of Biomedical Sciences, University of Padova, Padua, Italy
  • 9 Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany
  • 10 Institut für Laboratoriumsmedizin, Ludwig-Maximilians-Universität, Munich, Germany
  • 11 Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany
  • 12 Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary
  • 13 Department of Cardiology, Sarawak Heart Centre, Sarawak, Malaysia
  • 14 Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe-University, Frankfurt, Germany
  • 15 D. Swarovski Research Lab, Department of Visceral, Transplant Thoracic Surgery, Medical Univ Innsbruck, Innsbruck, Austria
  • 16 The Hatter Cardiovascular Institute, University College London, London, UK
  • 17 Department of Cardiology, Dong-A University Hospital, Busan, Korea
  • 18 Hatter Institute and MRC Inter-University Cape Heart Unit, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
  • 19 Institute for Molecular Cardiovascular Research, RWTH University Hospital, Aachen, Germany
  • 20 Department of Cardiology, The Rayne Institute, St Thomas' Campus, King's College London, London, UK
  • 21 The James Black Centre, King's College, University of London, London, UK
  • 22 Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
  • 23 Baker IDI Heart and Diabetes Institute, Melbourne, Australia
  • 24 Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
  • 25 Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol, UK
  • 26 Institute of Anatomy and Vascular Biology, Westfalian-Wilhelms-University, Münster, Germany
  • 27 Institute of Physiology, Justus-Liebig University, Giessen, Germany
  • 28 National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
  • 29 Department of Pathology, John A. Burns School of Medicine, University of Hawaii, Honolulu, USA
  • 30 Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, 8 College Road, Singapore, 169857, Singapore. derek.hausenloy@duke-nus.edu.sg
Basic Res Cardiol, 2016 11;111(6):69.
PMID: 27743118

Abstract

In this meeting report, particularly addressing the topic of protection of the cardiovascular system from ischemia/reperfusion injury, highlights are presented that relate to conditioning strategies of the heart with respect to molecular mechanisms and outcome in patients' cohorts, the influence of co-morbidities and medications, as well as the contribution of innate immune reactions in cardioprotection. Moreover, developmental or systems biology approaches bear great potential in systematically uncovering unexpected components involved in ischemia-reperfusion injury or heart regeneration. Based on the characterization of particular platelet integrins, mitochondrial redox-linked proteins, or lipid-diol compounds in cardiovascular diseases, their targeting by newly developed theranostics and technologies opens new avenues for diagnosis and therapy of myocardial infarction to improve the patients' outcome.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications